218 related articles for article (PubMed ID: 37212689)
1. Reduced Staphylococcus Abundance Characterizes the Lesional Microbiome of Actinic Keratosis Patients after Field-Directed Therapies.
Kehrmann J; Koch F; Zumdick S; Höwner A; Best L; Masshöfer L; Scharfenberg S; Zeschnigk M; Becker JC; Schadendorf D; Buer J; Roesch A
Microbiol Spectr; 2023 Jun; 11(3):e0440122. PubMed ID: 37212689
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the skin microbiome in normal and cutaneous squamous cell carcinoma affected cats and dogs.
Bromfield JI; Zaugg J; Straw RC; Cathie J; Krueger A; Sinha D; Chandra J; Hugenholtz P; Frazer IH
mSphere; 2024 Apr; 9(4):e0055523. PubMed ID: 38530017
[TBL] [Abstract][Full Text] [Related]
3. A Natural History of Actinic Keratosis and Cutaneous Squamous Cell Carcinoma Microbiomes.
Wood DLA; Lachner N; Tan JM; Tang S; Angel N; Laino A; Linedale R; Lê Cao KA; Morrison M; Frazer IH; Soyer HP; Hugenholtz P
mBio; 2018 Oct; 9(5):. PubMed ID: 30301852
[TBL] [Abstract][Full Text] [Related]
4. Skin Microbiome Variation with Cancer Progression in Human Cutaneous Squamous Cell Carcinoma.
Voigt AY; Emiola A; Johnson JS; Fleming ES; Nguyen H; Zhou W; Tsai KY; Fink C; Oh J
J Invest Dermatol; 2022 Oct; 142(10):2773-2782.e16. PubMed ID: 35390349
[TBL] [Abstract][Full Text] [Related]
5. Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications.
Feldman SR; Fleischer AB
Cutis; 2011 Apr; 87(4):201-7. PubMed ID: 21644496
[TBL] [Abstract][Full Text] [Related]
6. Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials.
Gollnick H; Dirschka T; Ostendorf R; Kerl H; Kunstfeld R
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):82-89. PubMed ID: 31407414
[TBL] [Abstract][Full Text] [Related]
7. Targeting
Bromfield JI; Hugenholtz P; Frazer IH; Khosrotehrani K; Chandra J
Front Oncol; 2023; 13():1091379. PubMed ID: 36816953
[TBL] [Abstract][Full Text] [Related]
8. Narrowband ultraviolet B response in cutaneous T-cell lymphoma is characterized by increased bacterial diversity and reduced
Hooper MJ; Enriquez GL; Veon FL; LeWitt TM; Sweeney D; Green SJ; Seed PC; Choi J; Guitart J; Burns MB; Zhou XA
Front Immunol; 2022; 13():1022093. PubMed ID: 36439132
[TBL] [Abstract][Full Text] [Related]
9. New and current preventive treatment options in actinic keratosis.
Arenberger P; Arenbergerova M
J Eur Acad Dermatol Venereol; 2017 Sep; 31 Suppl 5():13-17. PubMed ID: 28805940
[TBL] [Abstract][Full Text] [Related]
10. Changes in the skin microbiome associated with squamous cell carcinoma in transplant recipients.
Krueger A; Zaugg J; Lachner N; Bialasiewicz S; Lin LL; Gabizon S; Sobarun P; Morrison M; Soyer HP; Hugenholtz P; Frazer IH
ISME Commun; 2022 Feb; 2(1):13. PubMed ID: 37938715
[TBL] [Abstract][Full Text] [Related]
11. Contemporary management of actinic keratosis.
Navarrete-Dechent C; Marghoob AA; Marchetti MA
J Dermatolog Treat; 2021 Aug; 32(5):572-574. PubMed ID: 31621454
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a photolyase-based device in the treatment of cancerization field in patients with actinic keratosis and non-melanoma skin cancer.
Puviani M; Barcella A; Milani M
G Ital Dermatol Venereol; 2013 Dec; 148(6):693-8. PubMed ID: 24442053
[TBL] [Abstract][Full Text] [Related]
13. Targeted deep sequencing reveals genomic alterations of actinic keratosis/cutaneous squamous cell carcinoma in situ and cutaneous squamous cell carcinoma.
Kim YS; Jung SH; Park YM; Park GS; Kim HS; Maeng LS; Chung YJ
Exp Dermatol; 2023 Apr; 32(4):447-456. PubMed ID: 36533870
[TBL] [Abstract][Full Text] [Related]
14. The cutaneous microbiome in skin cancer - A systematic review.
Ding R; Lian SB; Tam YC; Oh CC
J Dtsch Dermatol Ges; 2024 Feb; 22(2):177-184. PubMed ID: 38243841
[TBL] [Abstract][Full Text] [Related]
15. Evidence for field cancerisation treatment of actinic keratoses with topical diclofenac in hyaluronic acid.
Ulrich M; Pellacani G; Ferrandiz C; Lear JT
Eur J Dermatol; 2014; 24(2):158-67. PubMed ID: 24721544
[TBL] [Abstract][Full Text] [Related]
16. Cyclin A and beta-catenin expression in actinic keratosis, Bowen's disease and invasive squamous cell carcinoma of the skin.
Brasanac D; Boricic I; Todorovic V; Tomanovic N; Radojevic S
Br J Dermatol; 2005 Dec; 153(6):1166-75. PubMed ID: 16307653
[TBL] [Abstract][Full Text] [Related]
17. Comparison of oxidative stress on DNA, protein and lipids in patients with actinic keratosis, Bowen's disease and squamous cell carcinoma.
Yoshifuku A; Fujii K; Kanekura T
J Dermatol; 2018 Nov; 45(11):1319-1323. PubMed ID: 30222205
[TBL] [Abstract][Full Text] [Related]
18. Risk of squamous cell carcinoma in immunosuppressed patients with voriconazole-related actinic keratosis.
Nobeyama Y; Umezawa Y; Asahina A
J Dermatol; 2022 Nov; 49(11):1168-1172. PubMed ID: 35986452
[TBL] [Abstract][Full Text] [Related]
19. Management of actinic keratosis at specific body sites in patients at high risk of carcinoma lesions: expert consensus from the AKTeam™ of expert clinicians.
Richard MA; Amici JM; Basset-Seguin N; Claudel JP; Cribier B; Dreno B
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):339-346. PubMed ID: 29235161
[TBL] [Abstract][Full Text] [Related]
20. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses.
Ulrich C; Johannsen A; Röwert-Huber J; Ulrich M; Sterry W; Stockfleth E
Eur J Dermatol; 2010; 20(4):482-8. PubMed ID: 20507841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
